CIM City: the Game Continues for a Better Carbapenemase Test

Romney M Humphries

doi:10.1128/JCM.00353-19

CIM City: the Game Continues for a Better Carbapenemase Test

J Clin Microbiol. 2019 Jun 25;57(7):e00353-19. doi: 10.1128/JCM.00353-19. Print 2019 Jul.

Author

Romney M Humphries^{1

2}

Affiliations

¹ Accelerate Diagnostics, Tucson, Arizona, USA rhumphries@axdx.com.
² University of Arizona, Department of Pathology, Tucson, Arizona, USA.

Abstract

The Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing agree that carbapenemase testing is not necessary for clinical care, provided that the laboratory is up to date with current breakpoints. Nonetheless, publication on the development and modification of carbapenemase tests continues, as is the case in this issue of the Journal of Clinical Microbiology (R. W. Beresford and M. Maley, J Clin Microbiol 57:e01852-18, 2019, https://doi.org/10.1128/JCM.01852-18). This commentary explores modifications to the carbapenem inactivation method-but is this the right focus for clinical laboratories?

Publication types

Comment

MeSH terms

Bacterial Proteins
Carbapenem-Resistant Enterobacteriaceae*
Carbapenems
beta-Lactamases

Substances

Bacterial Proteins
Carbapenems
beta-Lactamases
carbapenemase